Multiple Myeloma Program

The Penn Difference

Innovative Research…Advanced Medicine…Service Excellence

  • Nationally recognized experts with extensive experience in multiple myeloma
  • Advanced diagnostic testing, treatments and technologies
  • Coordinated care throughout the experience
  • Support services and education programs
  • A reputation for sensitivity and responsiveness
  • Personalized attention
  • Innovative clinical trials
  • The backing of a major research program with immediate translation to patient care

What sets Penn's Multiple Myeloma Program apart?

Penn’s program is one of the oldest and largest in the country. By putting our experience to work, we offer the best possible treatment outcomes.

Our multiple myeloma clinicians and researchers have dedicated their clinical and research careers to improving our ability to diagnose and treat patients with multiple myeloma.

It is this relentless pursuit for the very best clinical outcome and quality of life that drives Penn’s Multiple Myeloma Program.

Penn's program is distinguished in a number of ways:

  • Penn has one of the few Hematologic Malignancy (leukemia, lymphoma and myeloma) Research Programs in the country that is approved and funded by the National Cancer Institute.
  • The Multiple Myeloma Program, led by Edward Stadtmauer MD, is the largest program in the Delaware Valley and one of the largest in the nation.
  • Penn has one of the largest and most experienced teams of multiple myeloma specialists who have been working together for years.
  • Penn has a dedicated hospital unit that is not only well equipped to support transplant patients, but also experienced nurses who understand the personal issues faced during transplant.
  • Our doctors designed and oversaw trials sponsored by the National Cancer Institute and conducted by major centers nationwide. The results of these clinical trials prompted major changes in practice that reverberated throughout the nation.
  • Since the mid 1990's, Multiple Myeloma has become the most common indication for autologous transplant in North America. This is reflected in our clinical and research activity. Penn investigators have been in the forefront of the study of this modality in myeloma including CD34+ purging, adoptive immunotherapy with activated autologous T-cell infusions and the development of comparative trials of autologous and non-myeloablative allogeneic transplant for Multiple Myeloma.
  • In a clinical trial, the results of which were published in 2005, Penn investigators demonstrated for the first time the ability of activated T-cell infusions to re-establish immune function after transplant for Multiple Myeloma. This seminal finding has the potential to lead to tumor specific vaccine therapies for many different diseases.
  • The Program offers patients new therapies for the treatment of myeloma by translating the latest developments in drug discovery and laboratory into treatment approaches. Some of these innovative therapies include:
    • double autologous transplant versus autologous transplant followed by non-myeloablative allogeneic transplant;
    • immune-based therapy utilizing CD3/28 costimulated autologous T-cells infusion after autologous transplant;
    • new chemotherapy agents such as Bortezomib (Velcade) and Lemalimide (Revlimid) and
    • cutting edge investigations into novel agents such as Prolixin for Multiple Myeloma and antiCD40 monoclonal antibodies.
  • The Program has provided numerous educational symposia for patients and health care providers over the past several years as well as in the development of educational materials in association with the Patient and Family Services Program of the Abramson Cancer Center.
  • Dr. Stadtmauer is the medical advisor for the Philadelphia area Multiple Myeloma Networking Group which is among the largest support groups in the nation devoted to myeloma patients and their families.
  • Our clinicians have received numerous awards for their outstanding patient support activities.